INTRODUCTION
============

Necrotizing soft tissue infections (NSTIs) represent a spectrum of bacterial infections causing necrotic lesions in any layer of the soft tissue compartments. Each year, approximately 1,000 people are diagnosed with the disease in the United States ([@R1], [@R2]).

Nitric oxide (NO) is involved in a wide variety of regulatory mechanisms and exerts its physiological role through the cardiovascular, immune, and nervous systems ([@R3], [@R4]). NO is derived from the vascular wall and it is thought to contribute to hypotension in patients with sepsis, but it may also improve organ perfusion by microcirculatory vasodilation ([@R5], [@R6]). This could be of clinical importance as NSTI is often accompanied by septic shock and organ failure ([@R7]). However, the mechanisms linking NSTI to vascular dysfunction remain to be investigated. Interestingly, NO is also involved in the host--pathogen interactions through its function as a signaling molecule, antimicrobial agent, and downstream effector of innate immunity ([@R8]--[@R10]), thus potentially playing a role during NSTI.

NO is formed in the vascular endothelium by NO synthase (NOS) from [l]{.smallcaps}-arginine and oxygen. Once produced, NO (half-life \<2 ms) is rapidly oxidized to nitrite (NO~2~^−^) and nitrate (NO~3~^−^) in blood. Together, these two metabolites are widely used as an indirect measure of NO plasma levels ([@R11]--[@R13]). There is a growing interest in nitrite as it reflects constitutive NO availability ([@R14]) and provides a more reliable measure of endothelial NOS (eNOS) activity compared with nitrate ([@R15], [@R16]), whereas inducible NOS (iNOS) is thought to release an order of magnitude more NO in response to tissue damage and infection ([@R17], [@R18]). Therefore, nitrite assessment may aid in the early detection of endothelial dysfunction, but its prognostic role in critically ill patients has been sparsely evaluated due to the lack of sufficiently sensitive analytical methods ([@R19], [@R20]).

NOS activity is inhibited endogenously by asymmetric dimethylarginine (ADMA). An imbalance of NO (nitrite/nitrate), [l]{.smallcaps}-arginine, and ADMA is thought to be involved in endothelial and cardiac dysfunction ([@R21]). In line with this, high ADMA levels have been associated with increased mortality in patients with sepsis ([@R22]--[@R24]) and as an independent risk factor of intensive care unit (ICU) mortality ([@R25]), but data are conflicting ([@R26]). As ADMA competes with [l]{.smallcaps}-arginine for the binding to NOS, the [l]{.smallcaps}-arginine/ADMA ratio has been suggested as a better indicator to NOS substrate availability than [l]{.smallcaps}-arginine alone ([@R27]). NO, ADMA, and [l]{.smallcaps}-arginine are potential therapeutic targets and may be used in the identification of relevant subgroups of patients at high risk of poor outcome. To our knowledge, no studies have investigated the levels of these vasoactive biomarkers in patients with NSTI, despite the pathophysiological differences compared with other patients with sepsis. In addition, the treatment of NSTI often relies on knowledge from sepsis patients with pneumonia or other frequent sites of infection even though the immunological processes likely differ because of the extensive necrosis. Moreover, the diagnosis of NSTI is clinical which makes it interesting to investigate whether these biomarkers are able to predict patient outcome.

Accordingly, we evaluated the association between the level of NO system biomarkers in plasma and disease severity and outcome in patients with NSTI. The primary analysis focused on the association between nitrite level upon hospital admission (baseline) and septic shock. In the secondary analyses, we focused on the association between nitrite, [l]{.smallcaps}-arginine, ADMA, and [l]{.smallcaps}-arginine/ADMA ratio and disease severity as well as outcome, defined as use of renal replacement therapy (RRT), rates of amputation, and 28-day mortality.

MATERIALS AND METHODS
=====================

Study design and population
---------------------------

In Denmark, the treatment of NSTI has been centralized at Rigshospitalet, University of Copenhagen, where this prospective, observational cohort study was conducted between February 2013 and April 2015. The study protocol has been published ([@R28]) and is available online (ClinicalTrials.gov: NCT02180906).

We included patients diagnosed with NSTI, based on surgical findings of necrosis. Inclusion criteria included admission to the ICU or surgery for NSTI at Rigshospitalet and a minimum age of 18 years. Patients were excluded if the diagnosis could not be confirmed during surgery.

Data collection
---------------

Data were obtained from patient medical records and entered into an online database that was regularly validated. The following data were retrieved from the database: demographics (age, sex), comorbidities (diabetes, liver cirrhosis, chronic kidney disease, cardiovascular disease, chronic obstructive pulmonary disease, peripheral vascular disease, immune deficiency, malignancy, rheumatoid disease), biochemistry and physiological values, and disease severity scores (Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC), Simplified Acute Physiology Score (SAPS) II, Sepsis-Related Organ Failure Assessment (SOFA) score). Data on vital status (date of death or emigration) were retrieved from the Danish Civil Registration System. The presence of septic shock was defined according to Bone et al. ([@R29]) with at least two systemic inflammatory response syndrome (SIRS) criteria, suspected/verified focus of infection and vasopressor infusion.

Arterial blood was obtained in EDTA tubes upon hospital admission and immediately put on ice. After centrifugation, plasma was collected in 1 mL aliquots and stored at −80°C until processing. In 67% (n = 94) of the cases, baseline blood samples were collected after the primary operation of NSTI.

Chemiluminescent assay
----------------------

We quantified baseline plasma NO level indirectly through the measurement of nitrite using the ozone-chemiluminescence technology (Sievers Nitric Oxide Analyzer system, NOA 280i, GE Analytical Instruments, Boulder, Colo) as previously described ([@R30]). In brief, we thawed the plasma just before NO determination under the protection from light. We injected 300 μL plasma sample into the purge vessel of the NO analyzer containing glacial acetic acid and an iodide solution (NaI and KI), which converts nitrite to NO. Samples were tested in duplicates using a standard curve constructed with distilled water as blanks and sodium nitrite solutions of known concentrations (10 nM, 50 nM, 100 nM, 1 μM, 5 μM, 10 μM, 50 μM, and 100 μM), which yielded a linear relationship. The lower detection limit in the samples was ∼15 nM due to the nitrite content in the empty EDTA sampling tubes.

Enzyme-linked immunosorbent assay
---------------------------------

We measured baseline plasma ADMA and [l]{.smallcaps}-arginine using a competitive enzyme-linked immunosorbent assay (ELISA) (EA207/92; DLD Diagnostica GmbH, Hamburg, Germany) according to the manufacturer\'s instructions. Samples were tested in duplicate against a standard pool with known concentration. The standard range of ADMA was 0.2 to 3.0 μmol/L (normal values 0.40--0.75 μmol/L) with an intra-assay variation of 6% and interassay of 10%. The standard range of [l]{.smallcaps}-arginine was 5 to 300 μmol/L (normal values 20--80 μmol/L) with an intra-assay variation of 4% and interassay variation of 10%.

Statistical analysis
--------------------

Categorical data are presented as numbers with percentage (%) and compared using the chi-square test. Continuous data are presented as medians with interquartile range (IQR). We used the unpaired *t* test for the primary analysis to quantify potential differences between the groups and elaborate on a potential risk of overlooking a clinical relevant difference. As data were not normally distributed, we used the Mann--Whitney *U* test for significance testing of differences between groups ([@R28]). The association between 28-day mortality and biomarker levels are illustrated with Kaplan--Meier plots and tested using a logistic regression analysis and expressed with odds ratio (OR) and 95% confidence interval (CI). In the prediction of 28-day mortality, we analyzed both median values and optimal cutoff (maximum sum of sensitivity and specificity) ([@R28]). In the multivariate analysis, we adjusted for age, sex, comorbidities, and SAPS II. Patients with missing data on covariates were excluded in the multivariate analyses. No data were missing on the outcome variable, thus no multiple imputations were performed. We analyzed receiver operating characteristic (ROC) curves for 28-day mortality and Spearman rank test for correlation between biomarker level and disease severity.

P \< 0.05 was considered to be statistically significant. Analyses were performed using GraphPad Prism 6.0 software (Graphpad Inc., Calif) and SPSS 22.0 software (SPSS Inc., Ill).

Initially, we planned to include 110 patients based on a sample size calculation using total levels of nitrate and nitrite ([@R28]). As we aimed to measure only nitrite levels in the samples, this estimate is subject to great uncertainty, especially as no studies have investigated nitrite levels exclusively in infected patients using chemiluminescent. We therefore decided to analyze all samples obtained from patients with NSTI, who were included during the study period, as previously described ([@R7]). Baseline characteristics of the majority of the study cohort (n = 135) have been previously described in two studies elaborating on pattern recognition molecules ([@R7], [@R31]).

Ethics
------

The regional ethics committee (H-2-2014-071) and the Danish Data Protection Agency (30-1282) approved the study. All patients or their next of kin gave oral and written informed consent.

RESULTS
=======

We enrolled 171 patients with suspected NSTI between February 2013 and April 2015. Of those, 30 patients did not fulfill the inclusion criteria or fulfilled the exclusion criterion. Thus, we analyzed 141 baseline samples from patients with NSTI. The patients had a median age of 62 years (53--69) and 60% were men. The majority of patients presented with septic shock (72%) and 28-day mortality was 17% (n = 24 (95% CI, 12%--24%)). The median SAPS II was 45 (35--54) and could not be calculated in five patients due to missing data.

Disease severity
----------------

Patients with NSTI and septic shock had a mean baseline nitrite level of 0.88 μmol/L compared with 1.00 μmol/L in those without septic shock (mean difference 0.12 μmol/L (95% CI, --0.10 to 0.34), *P* = 0.83) and we found no significant difference between the groups using the Mann--Whitney *U* test (median 0.82 μmol/L, IQR 0.41--1.21 vs. 0.87 μmol/L, IQR 0.62--1.24, *P* = 0.25) (Fig. [1](#F1){ref-type="fig"}). Only baseline ADMA level was significantly higher in patients in need of RRT within the first 7 days of admission (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). This was in line with the correlation analyses showing that ADMA correlated significantly with the SAPS II and the SOFA score (Table [1](#T1){ref-type="table"}). In addition, nitrite, ADMA, and [l]{.smallcaps}-arginine/ADMA ratio correlated with creatinine levels.

![Plasma levels of nitrite, [l]{.smallcaps}-arginine, ADMA, and [l]{.smallcaps}-arginine/ADMA ratio on admission according to septic shock in patients with necrotizing soft tissue infection.](shk-49-667-g001){#F1}

![Plasma levels of nitrite, [l]{.smallcaps}-arginine, ADMA indicates and [l]{.smallcaps}-arginine/ADMA ratio on admission according to amputation and RRT within the first 7 days in patients with necrotizing soft tissue infection.](shk-49-667-g002){#F2}

Mortality
---------

Survival according to median biomarker levels and 28-day mortality is illustrated in Figure [3](#F3){ref-type="fig"} and the diagnostic accuracy is shown in Table [2](#T2){ref-type="table"}. Only a [l]{.smallcaps}-arginine/ADMA ratio below the median correlated significantly with the mortality, but it was not an independent predictor (Table [3](#T3){ref-type="table"}). However, when the optimal cutoff was used (maximum sum of sensitivity and specificity) instead of the median, the [l]{.smallcaps}-arginine/ADMA ratio independently predicted the 28-day mortality (Table [4](#T4){ref-type="table"}).

![Kaplan--Meier curves with related 95% CIs of 28-day mortality in patients with necrotizing soft tissue infection according to levels above or below median biomarker levels.](shk-49-667-g003){#F3}

DISCUSSION
==========

We found no difference in admission (baseline) plasma nitrite level according to septic shock in patients who had NSTI. In contrast, baseline ADMA level was associated with the use of RRT and it correlated with the SAPS II and the SOFA score. In line with this, patients with an [l]{.smallcaps}-arginine/ADMA ratio below 101.59 (optimal cutoff) upon hospital admission had 5 times the odds of dying within the first 28 days.

A main strength of this study is the full follow-up of the patients due to the individually assigned person number that is coupled to the national health registries. Furthermore, treatment of NSTI has been centralized at a national level at Rigshospitalet, University of Copenhagen, providing us with the opportunity to investigate the disease in a large but well-defined geographical area, increasing the external validity of the study.

A number of limitations need to be taken into consideration. First, the study might be subject to bias because of the inability to control for unknown confounders. We decided *a priori* to adjust for potential confounders (age, sex, comorbidities, and SAPS II) that most likely affect disease severity and mortality. It has previously been shown that kidney function has an impact on the nitrite, [l]{.smallcaps}-arginine, and ADMA levels in plasma ([@R32]), and this is confirmed in this study because there was a significant correlation between the biomarker levels and the creatinine levels. An adjustment for this was done as urine output and blood urea nitrogen levels are included in the SAPS II. Hemodilution may also be an important factor to consider. One would expect patients with severe illness (i.e., septic shock) to receive more fluids, thus influencing biomarker levels. Unfortunately, we do not have data on the amount on fluid resuscitation before the blood samples were obtained. However, in a previous study constituting the same cohort as this, we found no difference in hemoglobin levels in patients with and without septic shock ([@R7]), indicating that a potential diluting factor may not affect data significantly.

Second, five patients (3.5%) had missing SAPS II data and were not included in the multivariate analyses. No major changes were seen in OR when SAPS II was included in the final step of adjustment, thus making it unlikely for the missing values of the five patients to have a major impact. Moreover, we conducted multiple analyses, and the analyses regarding [l]{.smallcaps}-arginine, ADMA, [l]{.smallcaps}-arginine/ADMA ratio, and outcome were secondary in nature, thus increasing the risk of chance findings. Therefore, the diagnostic accuracy of the biomarkers should be tested in another cohort. It is also relevant to investigate these biomarkers in future cohorts defined by the Sepsis-3 Septic Shock definitions ([@R33]). In this study, most of the patients in the septic shock group (hypotension and receiving vasopressors) will probably also meet the Sepsis-3 definition as they also exhibited a lactate increase. However, the precise impact of the Sepsis-3 definition needs to be investigated in future studies. Importantly, we used the same criteria as previous studies investigating vasoactive biomarkers, which allow us to make relevant comparisons of the results and conclusions.

Third, the results from the logistic regression analyses had rather wide 95% CIs, thus complicating the interpretation. However, a low [l]{.smallcaps}-arginine/ADMA ratio upon hospital admission was associated with increased mortality and OR for death at Day 28 was approximately 5 as compared with patients with a high [l]{.smallcaps}-arginine/ADMA ratio. The [l]{.smallcaps}-arginine/ADMA ratio has been suggested as a superior indicator of NO dysfunction as the production of NO might be affected by abnormal levels of both [l]{.smallcaps}-arginine and ADMA ([@R21], [@R27]). There are conflicting data on the association between [l]{.smallcaps}-arginine, ADMA, and mortality in patients with sepsis and septic shock ([@R21], [@R22], [@R24], [@R26], [@R34]--[@R36]), but there seems to be a relatively consistent association between low [l]{.smallcaps}-arginine/ADMA ratio and mortality in infected patients ([@R21], [@R22], [@R34], [@R37]). However, the studies are limited by a small number of patients and the use of different time points of mortality assessment and different cutoff levels. A recent study investigating 267 patients with severe sepsis or septic shock found a significant association between high baseline ADMA levels and 90-day mortality, but no association between [l]{.smallcaps}-arginine/ADMA ratio and mortality ([@R38]). The results of that study may not be directly comparable to those of our study as the most frequent sources of infection in the former were the lungs and abdomen. In our study, all patients were severely infected in the soft tissues and/or muscles with associated tissue necrosis. It may be that the pathophysiology of these infections differs and that the response pattern from the NO system and the associated biomarkers varies.

In line with this, we are not able to establish a mechanistic explanation for our findings. However, the association between [l]{.smallcaps}-arginine/ADMA ratio and mortality could be attributed to the NO system. Endothelial cells regulate blood flow in microvessels by producing NO. Interestingly, the microcirculation is impaired in patients with septic shock and this is associated with higher mortality ([@R39], [@R40]). Moreover, NO production is stimulated by TNF-α and IL-1, and the level of both cytokines is increased in this group of patients and also associated with disease severity and mortality ([@R41]). It would have been interesting to investigate the NOS expression in these patients as the pronounced inflammation may be a significant inducer of inducible NOS, contributing to circulating NO metabolites ([@R42]).

We used nitrite level as a surrogate measure of NO production because the half-life of NO in blood is short making it difficult to measure ([@R43], [@R44]). In plasma, NO reacts with oxygen species to form nitrate and nitrite. Nitrite is the major oxidation product of NO in the absence of oxyhemoglobin or superoxide anion and may be a more reliable measure of eNOS activity than nitrate ([@R15], [@R16]). NO synthesis in vascular endothelial cells is of special interest as it reflects the microcirculation, thus making nitrite measurements relevant to our patients. Nitrate, on the contrary, is influenced by numerous factors, such as diet, the intestinal bacterial flora, and renal function. In addition, there are high concentrations of nitrate in plasma that makes it difficult to detect acute changes in accordance to eNOS ([@R45]). We are aware that the accuracy of the measurements are limited, but the purpose with this study was to determine whether clinically relevant differences exist between subgroups of patients with NSTI according to disease severity and mortality. Importantly, there seem to be an association between low substrate availability ([l]{.smallcaps}-arginine), high levels of NO inhibitor (ADMA), and mortality.

We speculate that this imbalance in the NO system contributes to an unfavorable impairment of the microcirculation of patients with NSTI causing organ failure and increased mortality. Further studies are needed to elucidate the precise mechanisms, but if endothelial dysfunction turns out to play a crucial role for clinical outcome, [l]{.smallcaps}-arginine and ADMA will be interesting biomarkers as well as the modulation of the NO pathway for this group of critically ill patients.

CONCLUSIONS
===========

In patients with NSTI, we found no difference in baseline nitrite level according to presence of septic shock. High baseline ADMA level was associated with use of RRT, and patients with a low baseline [l]{.smallcaps}-arginine/ADMA ratio were in higher risk of dying within first 28 days of hospital admission. Our findings support the hypothesis that the NO system plays an important role in the pathophysiology related to NSTI. However, this needs to be validated in other cohorts.
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###### 

Spearman rank correlation between disease severity scores and baseline biomarker levels in patients with necrotizing soft tissue infection

                          LRINEC   SAPS II   SOFA score[^\*^](#TF1-1){ref-type="table-fn"}   Creatinine[^\*\*^](#TF1-2){ref-type="table-fn"}                           
  ----------------------- -------- --------- ----------------------------------------------- ------------------------------------------------- ------- ------- ------- -------
  Nitrite                 −0.11    0.25      −0.13                                           0.15                                              −0.30   0.001   −0.23   0.009
  l-Arginine              −0.13    0.17      0.09                                            0.33                                              0.02    0.87    −0.12   0.17
  ADMA                    −0.05    0.59      0.32                                            0.0002                                            0.22    0.01    0.17    0.048
  l-Arginine/ADMA ratio   −0.07    0.43      −0.14                                           0.10                                              −0.12   0.18    −0.22   0.01

^\*^SOFA score day 1.

^\*\*^Highest value measured during the first 24 h of admission.

ADMA indicates asymmetric dimethylarginine; LRINEC, Laboratory Risk Indicator For Necrotizing Fasciitis; SAPS II, Simplified Acute Physiology Score II; SOFA, Sepsis-Related Organ Failure Assessment.

###### 

Diagnostic accuracy of high baseline nitrite and ADMA levels and low baseline [l]{.smallcaps}-arginine level and [l]{.smallcaps}-arginine/ADMA ratio in predicting 28-day mortality in patients with necrotizing soft tissue infection

                         Nitrite             l-Arginine          ADMA                l-Arginine/ADMA
  ---------------------- ------------------- ------------------- ------------------- -------------------
  Sensitivity            0.50 (0.31--0.69)   0.58 (0.39--0.76)   0.63 (0.42--0.80)   0.71 (0.51--0.86)
  Specificity            0.50 (0.46--0.54)   0.52 (0.48--0.56)   0.53 (0.48--0.56)   0.54 (0.50--0.58)
  PPV                    0.18 (0.11--0.25)   0.20 (0.13--0.27)   0.22 (0.15--0.28)   0.25 (0.18--0.30)
  NPV                    0.82 (0.75--0.89)   0.86 (0.79--0.92)   0.87 (0.80--0.93)   0.90 (0.83--0.95)
  Area under ROC curve   0.48 (0.34--0.62)   0.52 (0.38--0.65)   0.63 (0.51--0.75)   0.63 (0.53--0.73)

ADMA indicates asymmetric dimethylarginine; NPV, negative predictive value; PPV, positive predictive value. Data are presented as fractions (95% CI). The prevalence of 28-day mortality was 17%. High and low baseline levels were defined by the median.

###### 

Univariate and multivariate logistic regression analyses of mortality up to day 28 (time of censoring) in patients with necrotizing soft tissue infection based on high versus low concentrations of the biomarkers according to median values

                           Unadjusted   Adjusted for age, sex, chronic disease   Adjusted for sex, chronic disease, SAPS II[^\*^](#TF3-1){ref-type="table-fn"}                                                   
  ------------------------ ------------ ---------------------------------------- ------------------------------------------------------------------------------- ------ ------------ ------ ------ ------------- ------
  Nitrite                                                                                                                                                                                                        
   Low (≤0.82 μmol/L)      1                                                                                                                                     1                          1                    
   High (\>0.82 μmol/L)    1.00         0.41--2.42                               1.00                                                                            0.84   0.34--2.11   0.71   1.3    0.41--4.11    0.66
  l-Arginine                                                                                                                                                                                                     
   High (\>50.28 μmol/L)   1                                                                                                                                     1                          1                    
   Low (≤50.28 μmol/L)     1.50         0.62--3.66                               0.37                                                                            1.44   0.58--2.56   0.43   2.82   0.83--9.66    0.10
  ADMA                                                                                                                                                                                                           
   Low (≤0.54 μmol/L)      1                                                                                                                                     1                          1                    
   High (\>0.54 μmol/L)    1.85         0.75--4.58                               0.18                                                                            1.84   0.73--4.63   0.20   1.2    0.38--3.86    0.76
  l-Arginine/ADMA ratio                                                                                                                                                                                          
   High (\>89.38)          1                                                                                                                                     1                          1                    
   Low (≤89.38)            2.90         1.12--7.52                               0.029                                                                           2.59   0.98--6.85   0.06   3.07   0.90--10.48   0.07

^\*^Five patients were not included in the analysis due to missing data of SAPS II (one of whom died the first day of admission). When the missing variables were replaced with the minimal value and maximum value, the median SAPS II was 27 (18--44) and 37 (30--54), respectively, compared with 45 (35--54) for the entire cohort. Age is included in SAPS II.

ADMA indicates asymmetric dimethylarginine; CI, confidence interval; OR, odds ratio; SAPS II, Simplified Acute Physiology Score II.

###### 

Univariate and multivariate logistic regression analyses of mortality up to day 28 (time of censoring) in patients with necrotizing soft tissue infection based on high versus low concentrations of the biomarkers according to the optimal cutoff

                           Unadjusted   Adjusted for age, sex, chronic disease   Adjusted for sex, chronic disease, SAPS II[^\*^](#TF4-1){ref-type="table-fn"}                                                       
  ------------------------ ------------ ---------------------------------------- ------------------------------------------------------------------------------- ------- ------------- ------- ------- ------------- -------
  Nitrite                                                                                                                                                                                                            
   Low (≤1.49 μmol/L)      1                                                                                                                                     1                             1                     
   High (\>1.49 μmol/L)    2.20         0.62--7.85                               0.22                                                                            1.87    0.50--6.93    0.35    4.60    0.92--23.03   0.06
  l-Arginine                                                                                                                                                                                                         
   High (\>71.98 μmol/L)   1                                                                                                                                     1                             1                     
   Low (≤71.98 μmol/L)     0.59         0.23--1.54                               0.28                                                                            0.56    0.21--1.48    0.24    0.61    0.18--2.06    0.43
  ADMA                                                                                                                                                                                                               
   Low (≤0.40 μmol/L)      1                                                                                                                                     1                             1                     
   High (\>0.40 μmol/L)    11.5         1.50--88.41                              0.02                                                                            10.23   1.32--79.38   0.03    13.17   0.91--191     0.06
  l-Arginine/ADMA ratio                                                                                                                                                                                              
   High (\>101.59)         1                                                                                                                                     1                             1                     
   Low (≤101.59)           5.76         1.85--17.90                              0.003                                                                           5.02    1.59--15.91   0.006   6.03    1.41--25.84   0.016

^\*^Five patients were not included in the analysis due to missing data of SAPS II (one of whom died the first day of admission). When the missing variables were replaced with the minimal value and maximum value, the median SAPS II was 27 (18--44) and 37 (30--54), respectively. Age is included in SAPS II. Optimal cutoff was found by the maximum sum of sensitivity and specificity.

ADMA indicates asymmetric dimethylarginine; CI, confidence interval; OR, odds ratio; SAPS II, Simplified Acute Physiology Score II.
